Results 81 to 90 of about 150,694 (118)

A thymine-challenge test to prospectively evaluate dihydropyrimidine dehydrogenase activity for risk of severe 5-fluorouracil-induced gastrointestinal toxicity. [PDF]

Cancer Chemother Pharmacol
Helsby N, Sharples K, Kim YJ, Porter D, Burns K, Jeong SH, Benge S, Deva S, Lawrence B, Jackson C, North R, Strother RM, Duley J, Findlay M.   +13 more
europepmc   +1 more source

Oncology Specialists' Perceptions and Insights Into Dihydropyrimidine Dehydrogenase Testing in Palestine. [PDF]

Cancer Rep (Hoboken)
Dweib M, Hallak H, Hour H, Alzeer A, Fatafta R, Albaw L.   +5 more
europepmc   +1 more source

Cost-Effectiveness of Pre-emptive DPYD Genotyping Compared to Standard of Care Among Patients Receiving Fluoropyrimidine-Based Anti-cancer Treatment in Australia. [PDF]

Clin Drug Investig
Glewis S, Fagery M, Lingaratnam S, Harris S, Georgiou C, Underhill C, Warren M, Campbell R, Martin JH, Tie J, IJzerman M, Alexander M, Michael M.   +12 more
europepmc   +1 more source

Implementation of <i>DPYD</i> and <i>UGT1A1</i> Testing in Patients With GI Cancer: A Prospective, Nonrandomized Clinical Trial. [PDF]

JCO Precis Oncol
Tuteja S, Cayabyab MAS, Hoffecker G, Varughese LA, de Dieu Ndayishimiye J, Wittner VA, Wang X, Hatch R, Capozzi D, Harr M, Santani A, Hakonarson H, Watson D, Gabriel P, Doucette A, Massa R, Damjanov N, Reddy N, Oyer R, Teitelbaum UR.   +19 more
europepmc   +1 more source

A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report. [PDF]

BMC Med Genomics
Malekkou A, Tomazou M, Mavrikiou G, Dionysiou M, Georgiou T, Papaevripidou I, Alexandrou A, Sismani C, Drousiotou A, Grafakou O, Petrou PP.   +10 more
europepmc   +1 more source

Capecitabine-induced severe adverse events-therapeutic drug monitoring and <i>DPYD</i>-gene analysis are recommended. [PDF]

BMJ Case Rep
Perera J, Süsstrunk J, Thurneysen C, Steinemann D.   +3 more
europepmc   +1 more source

Global Investigation of Clinical Implementation Strategies for DPYD Testing to Guide Fluoropyrimidine Therapy. [PDF]

Clin Transl Sci
El Rouby N, Aquilante CL, Bargal SA, Cavallari LH, Duarte JD, Gunderson K, Mazhindu T, Nagy M, Nie X, Nguyen DG, Patel JN, Skaar TC, Smith DM, Tuteja S, van Schaik RHN, Hicks JK, PGRN Implementation Working Group.   +16 more
europepmc   +1 more source

Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5-year perspective from an EQA provider. [PDF]

Br J Clin Pharmacol
Roncato R, Perfler S, Pasin D, Peruzzi E, Woodcock M, Thomas H, Goodall R, Patton SJ, Cecchin E.   +8 more
europepmc   +1 more source

Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity. [PDF]

Pharmacogenomics J
Larrue R, Fellah S, Hennart B, Sabaouni N, Boukrout N, Van der Hauwaert C, Delage C, Cheok M, Perrais M, Cauffiez C, Allorge D, Pottier N.   +11 more
europepmc   +1 more source

The Role of Uridine in Health and Disease. [PDF]

J Inflamm Res
Song C, Liu ZJ, Xu B, Zou R, Hu W.
europepmc   +1 more source